monjuvihcp.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
User-agent: * Allow: / Sitemap: https://www.monjuvihcp.com/sitemap.xml Disallow: /pdf/abbreviated-brochure.pdf Disallow: /pdf/billing-and-coding-guide.pdf Disallow: /pdf/Caregiver-Brochure.pdf Disallow: /pdf/dlbcl-brochure.pdf Disallow: /pdf/dosage-and-administration-guide.pdf Disallow: /pdf/Dosage-and-Administration-Guide-Spanish.pdf Disallow: /pdf/hcp-leave-behind.pdf Disallow: /pdf/j-code-quick-reference-guide.pdf Disallow: /pdf/large-print-pi.pdf Disallow: /pdf/master-powerpoint-talon.pdf Disallow: /pdf/master-powerpoint.pdf Disallow: /pdf/medical-exceptions-and-patient-services-guide.pdf Disallow: /pdf/my-mission-support-enrollment-form.pdf Disallow: /pdf/my-mission-support-program-brochure.pdf Disallow: /pdf/nurse-leave-behind.pdf Disallow: /pdf/nurse-patient-discussion-guide.pdf Disallow: /pdf/patient-identification-flashcard.pdf Disallow: /pdf/Patient-Identification-Guide.pdf Disallow: /pdf/patient-profile-leave-behind-older-and-high-risk-patients.pdf Disallow: | ||
Meta Tags
| Title | MONJUVI® (tafasitamab-cxix): Treatment for R/R DLBCL | Official HCP |
| Description | SECURE RESPONSE IN SECOND MONJUVI® (tafasitamab-cxix) 200 mg for injection, targeted immunotherapy for intravenous use in R/R DLBCL and recommended by NCCN Guidelines®. Please see efficacy and safety data and the full PI, including Patient Information, for additional |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 40.71.199.117 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
monjuvihcp.com Valuation
|
US$5,806,233
Last updated: 2023-05-11 16:09:07
monjuvihcp.com has Semrush global rank of 1,822,921. monjuvihcp.com has an estimated worth of US$ 5,806,233, based on its estimated Ads revenue. monjuvihcp.com receives approximately 669,950 unique visitors each day. Its web server is located in United States, with IP address 40.71.199.117. According to SiteAdvisor, monjuvihcp.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$5,806,233 |
| Daily Ads Revenue | US$5,360 |
| Monthly Ads Revenue | US$160,788 |
| Yearly Ads Revenue | US$1,929,456 |
| Daily Unique Visitors | 44,664 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| monjuvihcp.com. | A | 599 | IP: 40.71.199.117 |
| monjuvihcp.com. | NS | 86400 | NS Record: ns.udag.net. |
| monjuvihcp.com. | NS | 86400 | NS Record: ns.udag.de. |
| monjuvihcp.com. | NS | 86400 | NS Record: ns.udag.org. |
| monjuvihcp.com. | MX | 3600 | MX Record: 20 mx02.morphosys.com. |
| monjuvihcp.com. | MX | 3600 | MX Record: 10 mx01.morphosys.com. |
| monjuvihcp.com. | TXT | 600 | TXT Record: D497572210F3181359685E7EA3615D5F2713BDBE95F7918D987A0E2924C60142 |
HtmlToTextCheckTime:2023-05-11 16:09:07
| INDICATIONS & USAGE INDICATIONS & USAGE: MONJUVI (tafasitamab-cxix), in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). This site is for US healthcare professionals MONJUVI Prescribing Information Patient Site My MISSION Support Program Contact a Representative Visit our Facebook page Navigate to homepage Navigate to homepage Patient Identification Efficacy Safety Dosage About Monjuvi Overview Moa FAQ Resources Educational Materials Videos Treatment Tracker Billing and Coding My Mission Support MONJUVI Prescribing Information |
HTTP Headers
HTTP/1.1 301 Moved Permanently Content-Length: 0 Content-Type: text/html; charset=UTF-8 Location: https://monjuvihcp.com/ Date: Fri, 05 Nov 2021 08:52:18 GMT HTTP/2 301 cache-control: public, max-age=604800 content-length: 150 content-type: text/html; charset=UTF-8 location: https://www.monjuvihcp.com/ server: Microsoft-IIS/10.0 x-powered-by: ASP.NET set-cookie: ARRAffinity=5d37913d57e0f627923ac44721a8fa6b754e0b8bdcb7e12ac40c0d461cb413bf;Path=/;HttpOnly;Secure;Domain=monjuvihcp.com set-cookie: ARRAffinitySameSite=5d37913d57e0f627923ac44721a8fa6b754e0b8bdcb7e12ac40c0d461cb413bf;Path=/;HttpOnly;SameSite=None;Secure;Domain=monjuvihcp.com date: Fri, 05 Nov 2021 08:52:18 GMT HTTP/2 200 cache-control: public, max-age=604800 content-length: 0 content-type: text/html; charset=UTF-8 server: Microsoft-IIS/10.0 x-powered-by: PHP/7.3.29 x-powered-by: ASP.NET set-cookie: ARRAffinity=5d37913d57e0f627923ac44721a8fa6b754e0b8bdcb7e12ac40c0d461cb413bf;Path=/;HttpOnly;Secure;Domain=www.monjuvihcp.com set-cookie: ARRAffinitySameSite=5d37913d57e0f627923ac44721a8fa6b754e0b8bdcb7e12ac40c0d461cb413bf;Path=/;HttpOnly;SameSite=None;Secure;Domain=www.monjuvihcp.com date: Fri, 05 Nov 2021 08:52:18 GMT |
monjuvihcp.com Whois Information
Domain Name: MONJUVIHCP.COM Registry Domain ID: 2411995070_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.udag.net Registrar URL: http://www.united-domains.de Updated Date: 2021-11-03T04:11:42Z Creation Date: 2019-07-12T11:21:04Z Registry Expiry Date: 2022-07-12T11:21:04Z Registrar: United-Domains AG Registrar IANA ID: 1408 Registrar Abuse Contact Email: abuse@united-domains.de Registrar Abuse Contact Phone: +49.8151368670 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: NS.UDAG.DE Name Server: NS.UDAG.NET Name Server: NS.UDAG.ORG DNSSEC: unsigned >>> Last update of whois database: 2021-11-05T06:25:35Z <<< |